Plasma B-Cell Maturation Antigen Levels are Elevated and Correlate with Disease Activity in Patients with Chronic Lymphocytic Leukemia

  title={Plasma B-Cell Maturation Antigen Levels are Elevated and Correlate with Disease Activity in Patients with Chronic Lymphocytic Leukemia},
  author={Kyle A. Udd and Sean Elliott Bujarski and Eric Wirtschafter and Tanya M. Spektor and Matthew Ghermezi and Laura Rassenti and Michael David and Jason D. Nosrati and Ashkon Rahbari and James Wang and Suzie Vardanyan and Nika Manik Harutyunyan and Julia Linesch and Mingjie Li and Eric Sanchez and Haiming Chen and Thomas J. Kipps and James R. Berenson},
  journal={Targeted Oncology},
  pages={551 - 561}
Chronic lymphocytic leukemia (CLL) is a malignancy of late B cells. In another late B-cell malignancy (multiple myeloma), levels of solubilized B-cell maturation antigen (sBCMA) are elevated and predict outcomes. We sought to evaluate sBCMA as a possible prognostic factor and monitoring tool for patients with CLL. Using an enzyme-linked immunosorbent assay (ELISA), we assessed plasma (p) levels of BCMA in 171 CLL patients and compared them with levels in healthy individuals. pBCMA levels were… 
The clinical significance of B-cell maturation antigen as a therapeutic target and biomarker
This BCMA review encompasses full-text publications of original research articles and abstracts presented at hematology/oncology meetings and shows great promise for BCMA-directed therapies with promising clinical results.
Mass spectrometry-based identification of a B-cell maturation antigen-derived T-cell epitope for antigen-specific immunotherapy of multiple myeloma
The naturally presented HLA-B*18-restricted ligand P(BCMA) B*18 was identified on primary CLL samples, thereby expanding the range for possible applications and representing a promising target for T-cell-based immunotherapy and monitoring following immunotherapy in B-cell malignancy patients.
Identification of the key genes and pathways involved in B cells in primary Sjögren’ s syndrome
A diagnostic model for Primary Sjögren’ s syndrome is constructed and validated by using the expression patterns of these key genes, which may assist clinicians in diagnosing pSS.
Endogenous soluble receptors sBCMA and sTACI: biomarker, immunoregulator and hurdle for therapy in multiple myeloma.
Insights into the biochemical mechanism of shedding of BCMA can be harnessed to improve BCMA-directed therapy by blocking its shedding with a γ-secretase inhibitor.


Serum B-Cell Maturation Antigen As a Biomarker for Chronic Lymphocytic Leukemia Treated with Ibrutinib
Assessment of B-cell maturation antigen in CLL patients during treatment with ibrutinib found decrease in sBCMA was associated with reduction in lymphadenopathy, while an increase in s BCMA from nadir often preceded clinical PD.
Serum B‐cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival
Serum BCMA levels were found to be higher in the supernatants of cultured bone marrow mononuclear cells from multiple myeloma patients than in healthy subjects, and levels correlated with the change in tumour volume in response to melphalan or cyclophosphamide with bortezomib.
Serum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patients
Serum B-cell maturation antigen levels did not show any dependence on renal function and maintained independent significance when tested against other known prognostic markers for multiple myeloma such as age, serum β2 microglobulin, hemoglobin, and bone disease.
Changes in Serum B-Cell Maturation Antigen Levels Rapidly Indicate Changes in Clinical Status Among Multiple Myeloma Patients Undergoing New Treatments
Compared changes in levels of sBCMA with sM-protein among MM patients undergoing new treatments, there is a need for more rapid and accurate ways to assess the efficacy of new therapies.
Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia.
An analysis of 23 prognostic markers based on prospectively collected data from 1948 CLL patients participating in phase 3 trials of the German CLL Study Group to develop a comprehensive prognostic index with high discriminatory power and prognostic significance on the individual patient level is developed.
Unmutated Ig VH Genes Are Associated With a More Aggressive Form of Chronic Lymphocytic Leukemia
Despite having several characteristics of naı̈ve B cells, chronic lymphocytic leukemia (CLL) cells have been shown in some cases to have somatically mutated Ig variable region genes, indicating that
Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia.
Despite having several characteristics of naïve B cells, chronic lymphocytic leukemia (CLL) cells have been shown in some cases to have somatically mutated Ig variable region genes, indicating that
Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival.
Evidence that B-lymphocyte stimulator (BLyS) can modulate the proliferative capacity and survival of MM cells is provided and evidence that BLyS is expressed by MM cells and is present in the bone marrow of patients with MM.
Humoral immune failure defined by immunoglobulin class and immunoglobulin G subclass deficiency is associated with shorter treatment‐free and overall survival in Chronic Lymphocytic Leukaemia
Data suggest aspects of immune deficiency correlate with disease severity and may be associated with shorter treatment‐free survival (TFS) in CLL.
Characteristics associated with important clinical end points in patients with chronic lymphocytic leukemia at initial treatment.
  • W. Wierda, S. O'brien, +11 authors M. Keating
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2009
Identifying pretreatment patient characteristics associated with CR, TTF, and OS establishes a baseline to compare and incorporate new prognostic factors and may help patients and clinicians in decision making as well as facilitate clinical research through design and analyses of clinical trials.